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 ABSTRACT 
 The objectives of the study were to define the sen-
sitivity and specificity of the California Mastitis Test 
(CMT) in determining the presence of intramammary 
infection in postpartum dairy goats and to determine 
whether antibiotic therapy increased bacteriological 
cure rate and lowered somatic cell count (SCC) com-
pared with untreated controls. A CMT was performed 
and milk samples were collected for bacteriology from 
211 glands of 106 does between 0 and 10 d after kid-
ding. From a population of 3,239 glands from goats 
in 4 commercial herds, goats with one or both glands 
with a CMT score of >1 and from which bacteria 
were isolated were either assigned to be treated with 
3 intramammary infusions at 12-h intervals of 75 mg 
of sodium ampicillin and 250 mg of sodium cloxacillin 
(n = 57 glands) or left as untreated controls (n = 49 
glands). Milk samples were collected again 14 ± 3 and 
21 ± 3 d later for bacteriology and SCC determination. 
Composite milk yield, goat SCC, length of lactation, 
and survival data were collected. A partial budget was 
constructed to assess the cost effectiveness of treatment. 
At a cut point of greater than trace, the sensitivity, 
specificity, and positive and negative predictive values 
of the CMT were 0.74, 0.74, 0.42, and 0.92, respectively. 
Treatment increased the bacteriological cure rate com-
pared with no treatment [30/57 (53%) vs. 6/49 (12%)], 
but there was a pathogen by treatment interaction 
whereby treatment increased cure proportion in glands 
infected with minor, but not major, pathogens. Treat-
ment reduced the foremilk gland-level SCC [1,595 (95% 
CI = 1,106–2,300) vs. 3,028 (95% CI = 2,091–4,385) 
geometric mean (× 1,000) cells/mL] but not the SCC 
at goat level [1,596 (95% CI = 1,219–2,090) vs. 1,488 
(95% CI = 1,132–1,955) geometric mean (× 1,000) 
cells/mL] compared with no treatment. Milk yield, 
risk of removal from the herd, and length of lactation 
were not altered by treatment. Treatment resulted in a 
loss of NZ$20.39/doe. It was concluded that use of the 
CMT as a screening test resulted in a higher likelihood 
of finding a gland that would be infected than selecting 
a gland at random. Treatment increased bacteriological 
cure rate and reduced SCC at gland level compared 
with no treatment. However, at goat level, milk yield, 
SCC, and survival were not altered, resulting in no 
economic benefit of treatment. 
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 INTRODUCTION 
 The prevalence of subclinical mastitis in dairy goats 
ranges between 5 and 30% (Contreras et al., 2007), with 
CNS being the most prevalent isolates (Kalogridou-
Vassiliadou, 1991; White and Hinckley, 1999; Contreras 
et al., 2007). Staphylococcus aureus is also commonly 
isolated, but in the majority of studies its prevalence is 
lower than that of CNS (Contreras et al., 2007). How-
ever, S. aureus appears to induce a higher SCC than 
most of the CNS species (Deinhofer and Pernthaner, 
1995) and is considered a major pathogen in goats. 
 Somatic cell count is commonly used as a milk qual-
ity standard at the individual animal and herd level. 
Somatic cell count is higher in doe glands from which 
bacteria are isolated (Contreras et al., 1996; White and 
Hinckley, 1999), and this is associated with an influx 
of neutrophils (Droke et al., 1993). However, SCC ap-
pears to increase in later lactation and in older goats, 
even in the absence of IMI (Wilson et al., 1995). Estrus 
(McDougall and Voermans, 2002), caprine arthritis en-
cephalitis virus (Ryan et al., 1993), and stressors such 
as vaccination (Lerondelle et al., 1992) also increase 
SCC in goats. 
 Somatic cell count is inversely related with milk yield 
(Zeng and Escobar, 1995), and increased SCC affects 
milk composition in does (Raynal-Ljutovac et al., 2007). 
Increased SCC and California Mastitis Test (CMT) 
scores were associated with increased milk pH, and a 
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CMT score >2.5 resulted in lower cheese yields (Galina 
et al., 1996). Half-udder milk yield was approximately 
35% lower and SCC was 4-fold higher following deliber-
ate infection with CNS (Leitner et al., 2004). Using 
structural equation modeling, which allows for bidirec-
tional effects of 2 variables on each other, as well as 
repeated measures associations, it was estimated that a 
1-unit increase in log base 2 SCC was associated with a 
16 to 20 g/gland per day decrease in doe milk yield (de 
los Campos et al., 2006).
The CMT score, an indirect measure of SCC, is well 
correlated with SCC in goats (Maisi, 1987; Contreras 
et al., 1996). Additionally, the CMT score is positively 
associated with the presence of an IMI; glands with 
a CMT score >0 have sensitivity, specificity, positive 
predictive value, and negative predictive value of 0.79, 
0.67, 0.38, and 0.93, respectively, when assessed at 6 wk 
after kidding (McDougall et al., 2001). In dairy cattle, 
a rapid decline in gland-level SCC occurs in the first 
10 d postpartum along with an associated decrease in 
sensitivity and increase in specificity for detection of 
IMI using SCC. The effect of DIM on CMT score is 
less clear (Sargeant et al., 2001). The test characteris-
tics of the CMT appear not to have been assessed in 
goats in the first week postpartum. The CMT test has 
the advantages of being undertaken beside the animal 
rapidly and with minimal cost. Thus, CMT may have 
a role as a screening test to identify goats for further 
examination (e.g., bacteriology) or to withhold them 
from supply to maintain an acceptable bulk milk SCC.
Intramammary infections with CNS may persist for 
extended periods of time, with the same isolate present 
for up to 7 mo (Contreras et al., 1997). Treatment of 
IMI may increase cure rate and result in a lower SCC 
and higher milk yields compared with no treatment. 
The objectives of this study were to define the sensitiv-
ity and specificity of the CMT in diagnosing IMI in 
the first 10 d after kidding and to assess the efficacy of 
treatment of IMI early in lactation in dairy goats.
MATERIALS AND METHODS
These studies were undertaken with approval of the 
Animal Ethics Committee of AgResearch Ruakura 
(Hamilton, New Zealand). Spring-kidding dairy goat 
herds (n = 4) in which herd owners undertook milk 
production recording (herd testing), maintained records 
of treatments of goats, and were willing to be involved 
were enrolled. To assess the test characteristics of 
CMT, foremilk samples were collected by technicians 
for microbiology, SCC, and CMT between 0 and 10 d 
after kidding from a subset of 106 goats (211 glands) 
from the 4 herds.
Effect of Treatment on Bacteriological  
Cure, SCC, and Production
In a treatment study, the CMT score on a scale of 
0, trace, 1, 2, or 3 was determined for each gland (n 
= 3,239) of goats (from 4 herds) that had been kid-
ded 1 to 4 d. Each gland was sampled at only 1 time 
point. From those with a CMT score >1, 1 foremilk 
milk sample (~5 mL) was collected for bacteriology 
and a second foremilk sample (~25 mL) was collected 
for SCC determination. When a gram-positive major 
mastitis pathogen (i.e., S. aureus or Streptococcus spp.) 
was isolated, the goat was either assigned to treatment 
or left as an untreated control. Additionally, a random 
sample of one of 2 sequential goats from which CNS or 
Corynebacterium spp. (minor pathogens) were isolated 
was either assigned to be treated or left as an untreated 
control as above. Treatment was assigned at the goat 
level, so where 2 glands from the same goat were en-
rolled, both were either treated or left untreated.
Treatment consisted of 3 intramammary infusions at 
12-h intervals of 75 mg of sodium ampicillin and 250 
mg of sodium cloxacillin (Lactaclox, Norbook Animal 
Health, Auckland, New Zealand). Milk was withheld 
for 108 h (9 milkings) after administration of the third 
infusion. Treatment (d 0) occurred 3 or 4 d after initial 
sample collection. At 14 ± 3 and 21 ± 3 d after initia-
tion of treatment, foremilk samples were collected for 
bacteriology and SCC determination from each enrolled 
gland. Records including herd testing data, disease 
dates and reasons, removals (culls or deaths) with dates 
and reasons, final milking date, and subsequent kidding 
dates were recovered.
Laboratory Procedures
Following gentle inversion of the milk sample, 10 μL 
of milk was spread onto a quadrant of a 0.1% esculin, 
5% sheep blood agar plate (Fort Richard, Auckland, 
New Zealand). All samples were incubated for 48 h at 
37°C before assessment at 48 h. Any isolate present 
with >2 colonies/plate was speciated per NMC (1999) 
recommendations. A sample was defined as contami-
nated when >3 distinct colony types of bacteria were 
present. A gland was defined as cured where the patho-
gen isolated from the pretreatment sample was not 
isolated from either of the posttreatment samples. In 
the 2 glands in which there were 2 isolates pretreatment 
(in both cases a Streptococcus uberis and a CNS, with 1 
gland from each treatment group), the gland was coded 
as infected with Strep. uberis for descriptive purposes, 
but cure was defined considering both isolates. In one 
case cure occurred (no bacteria were isolated from ei-
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ther posttreatment sample), whereas in the other case 
Strep. uberis was isolated once posttreatment, so the 
gland was defined as uncured. Initially, all CNS were 
treated as 1 group, ignoring the species identity. How-
ever, following species identification (see below), cure 
for each gland infected with CNS was reassessed with 
knowledge of the specific CNS species. At goat level, 
cure was defined as occurring when both glands were 
cured if 2 glands were enrolled. A gland was defined 
as having acquired a new IMI if a bacterial species not 
isolated at enrollment was isolated in either of the post-
treatment samples.
A total of 121 CNS isolates from both pre- (n = 
57) and posttreatment (n = 64) from glands that were 
included in the treatment study were subcultured and 
DNA was extracted as described by Űnal et al. (1992) 
after 24 h of growth. The CNS species were defined us-
ing transfer RNA-intergenic spacer PCR (tDNA-PCR) 
in combination with capillary electrophoresis, supple-
mented with sequencing of the rpoB housekeeping gene 
if needed (Supré et al., 2009). The SCC was determined 
by a fluoro-optic method (Foss 5000, Foss, Hillerød, 
Denmark). To demonstrate a 30% difference in bac-
teriological cure rate between treated and untreated 
glands, 45 cases/treatment group were required at α 
(P-value) = 0.05 and β (1 – power) = 0.2.
Statistical Analysis
Relationship Between IMI, SCC, and CMT. 
The relationship between the CMT score and the prob-
ability of an IMI was analyzed by chi-squared following 
dichotomization of the CMT scores as >0, greater than 
trace, >1, or >2. The sensitivity, specificity, positive 
predictive value, and negative predictive value were 
calculated using standard techniques and the 95% con-
fidence intervals were estimated (Wilson, 1927). The 
relationship was further examined by creating receiver 
operator curves. The relationships between log base 2 
SCC and CMT score, DIM (coded as 0–1, 2, 3, and ≥4 
d), age (coded into quintiles of approximately similar 
group sizes: 1, 2–3, 4–7, and >7 yr), and IMI were ini-
tially evaluated by 1-way ANOVA and all were signifi-
cantly associated. However, because gland was clustered 
within goat and goat within herd, a linear mixed model 
was created with gland and goat as random effects and 
with the CMT score (coded as 0, trace, 1, and 2 and 
3) and herd as fixed effects. A separate linear mixed 
model was run to examine the effect of DIM and IMI 
status (infected vs. not infected) on log base 2 SCC.
Effect of Treatment on Cure, SCC, and Pro-
duction. Treatment group balance was assessed using 
ANOVA for continuous variables and chi-squared for 
categorical variables. The distribution of the CNS spe-
cies between treatment groups and among herds was 
compared using chi-squared.
Bacteriological cure rate was analyzed using Mantel-
Haenszel analysis with treatment group as the main 
effect and stratified by pathogen type (i.e., minor vs. 
major). The analysis was initially undertaken using cure 
databased on CNS at genus level and then repeated 
with knowledge of the CNS species.
The SCC in foremilk on d 14 and 21 were log base 
2 transformed for analysis. Variables associated at the 
univariate level (P < 0.2) were included in a linear 
mixed model with herd, treatment, sample time, and 
IMI categorized as minor or major as fixed effects, 
gland within goat as a random effect, and sample time 
as a repeated measure.
The associations between survival (i.e., the goat was 
in the herd in the subsequent lactation) and treatment, 
herd, age (coded into quartiles of approximately similar 
group sizes: <3, 3–4, 5–7, and >7 yr old), Julian kidding 
date (as a categorical variable), IMI (coded as minor or 
major), and number of glands within the goat enrolled 
(i.e., 1 or 2) were initially tested for bivariate associa-
tion with cure. Variables found to be associated (P < 
0.2) were offered to reverse stepwise logistic regression 
model using likelihood ratio as the inclusion-exclusion 
criteria. First-order interactions between the treatment 
group and the other main effects left in the model were 
examined. The length of lactation was analyzed using 
Kaplan Meier survival analysis and the effect of treat-
ment on lactation length was tested using the log rank 
test.
The goat-level log base 2 SCC and untransformed 
milk solids production (i.e., fat and protein; kg/goat 
per day) data from each of the 4 production recordings 
(herd tests) that occurred at 47 (SD = 15), 113 (SD 
= 19), 182 (SD = 13), and 240 (SD = 15) DIM were 
analyzed in linear mixed models with goat as a random 
effect and herd, treatment, age (coded as <3, 3–4, 5–7, 
and >7 yr old), herd test number, and IMI pathogen 
type as fixed effects. Herd test number was treated as 
a repeated measure and an autoregressive 1 covariance 
structure was used.
Data from the above models are presented as esti-
mated marginal means, SEM, and standard errors of 
the difference, from which geometric means and SEM 
were calculated as required (i.e., for the log-transformed 
SCC data). Pairwise comparisons between levels of in-
cluded variables were undertaken using the Bonferroni 
adjustment for multiple comparisons.
A partial budget for treatment of the goats was 
developed. The current (2009) payment to producers 
in New Zealand is NZ$12/kg of milk solids (i.e., fat, 
protein, and lactose). It was assumed that benefits 
would include a reduced log base 2 SCC during the 21 
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d after treatment, and this was adjusted by the average 
number of glands in enrolled does (1.4) as was found 
in the current study. Another assumption was that no 
compensatory increase in production would occur where 
1 gland was unaffected. The average daily milk solids 
production (fat and protein yield as kg/doe per day) of 
all does from the 4 herds was 0.16 kg/doe per day in the 
current study. The total milk solids (i.e., fat, protein, 
and lactose) from these goats was then estimated using 
the milk composition data of Zeng and Escobar (1995), 
who found that fat and protein constituted about 63% 
of the total milk solids. Thus, the average daily milk 
solids production was 0.25 kg/doe per day. Each unit 
increase in the log base 2 SCC is reported to reduce 
daily milk yield by 16 g/doe per day (de los Campos et 
al., 2006). It was assumed that the treatment resulted in 
an additional 10 d of lactation (see below). Additional 
costs included the cost of treatment (3 treatments at 
NZ$5/treatment), labor cost (NZ$1/treatment), the 
cost of undertaking the CMT (NZ$0.39/test), and the 
cost of microbiology (NZ$8/sample). Reduced revenue 
was attributed to the milk discard period of 4.5 d. No 
reduced costs associated with reduced risk of clinical 
or new subclinical IMI or for reduced culling were as-
sumed. The cost benefit was then calculated as (ex-
tra revenue + reduced costs) − (reduced revenue + 
increased costs). Statistical analyses were undertaken 
using SPSS (v. 18, SPSS Inc., Chicago, IL).
RESULTS
Relationship Between IMI, SCC, and CMT
The prevalence of IMI was 43/211 (20.4%) glands. 
Infections were with CNS (n = 17; 8%), Corynebacte-
rium spp. (n = 23; 11%), S. aureus (n = 2; 1%), and 
Strep. uberis (n = 1; 0.5%).
The frequency (%) of CMT scores was 89 (42%), 
46 (22%), 28 (13%), 43 (20%), and 6 (3%) for scores 
0, trace, 1, 2, and 3, respectively. The sensitivity and 
negative predictive value increased, and the specificity 
and positive predictive value increased, with increasing 
CMT cut off above which the test was declared posi-
tive (Figure 1a and b). The test characteristics did not 
change by DIM (P = 0.32; Figure 1c and d) and there 
was no DIM by CMT interaction (P = 0.11) when a 
score >1 was used as the cut point. The area under 
the receiver operator curve was 0.80 (SE = 0.04) and 
the CMT was significantly better than no test at pre-
dicting the presence of an IMI (P < 0.001; Figure 2). 
The highest sensitivity and specificity occurred at a cut 
point >1 where the sensitivity and specificity were 0.63 
and 0.87, respectively, at which point Youden’s index 
(i.e., sensitivity + specificity − 1; Thrusfield, 2005) was 
maximal.
Log base 2 of foremilk SCC was positively associated 
with the CMT score (P < 0.001; Figure 3a). The log 
base 2 SCC was higher in infected glands than in un-
infected glands [2,006 (95% CI = 1,079–3,750) vs. 484 
(95% CI = 346–3,676) × 1,000 cells/mL; P < 0.001] 
and tended to decline with DIM (P = 0.07; Figure 3b). 
There was no interaction of DIM with IMI status (P 
= 0.71; Figure 3b), and herd was not significant (P = 
0.10).
Effect of Treatment on Bacteriological Cure,  
SCC, and Production
Of the 3,239 glands examined, 512 (15.8%) had a 
CMT score >1; from these, 506 samples were collected 
for bacteriology. Of these, 233 (46%), 174 (34%), and 
65 (13%) isolated no bacteria, CNS, and Corynebacte-
rium spp., respectively (Table 1). A total of 57 of the 
pretreatment CNS were identified to species level as 
Staphylococcus simulans (55%), Staphylococcus epider-
midis (13%), Staphylococcus caprae (12%), Staphylococ-
cus lugdunensis (10%), Staphylococcus hyicus (3%), and 
Staphylococcus cohnii ssp. urealyticus, Staphylococcus 
warneri, and Staphylococcus xylosus (each 2%). No dif-
ference in distribution of the CNS species was found 
between the treatment groups (P = 0.61). However, 
variation did exist among herds in the distribution of 
CNS species (P < 0.01).
Gland Level. A total of 106 glands (49 in the con-
trol and 57 in the treatment group) met the final enroll-
ment criteria and were resampled posttreatment (Table 
2). No significant differences were found between the 
groups, but the treatment group tended (P = 0.07) 
to be sampled earlier postkidding and to have more 
Saanens. The kidding date did not differ [July 16 (SEM 
= 1.7 d) vs. July 19 (SEM = 1.7 d) for the control 
and treatment groups, respectively; P = 0.26] and there 
was no difference in the gland-level log10 foremilk SCC 
before treatment [3.98 (SEM = 0.05) vs. 3.99 (SEM 
= 0.05) for the control and treatment groups, respec-
tively; P = 0.88].
The overall cure proportion was higher for treated 
glands than for control glands [30/57 (52.6%) vs. 6/49 
(12.2%)]. However, a treatment group by pathogen 
type interaction (P < 0.001) existed whereby treat-
ment resulted in a higher cure proportion than controls 
for glands infected with a minor pathogen (P < 0.001; 
Table 3), but no difference in cure proportion was found 
between treated and control glands for glands infected 
with a major pathogen (P = 0.10; Table 3).
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When the cure proportion was reanalyzed using the 
CNS species rather than the genus level designation, in 
only 1 case did the cure outcome change. In this case 
S. caprae was isolated pretreatment and S. simulans 
was isolated twice post treatment and the gland was 
reclassified as having cured.
New IMI were found in 7 of 106 (6.6%) glands. Six 
of the new IMI were attributed to CNS and 1 was at-
tributed to yeast. Glands initially infected with a major 
pathogen tended to be more likely to acquire a new 
IMI (major or minor) than glands previously infected 
with a minor IMI [3/22 (13.6%) vs. 3/84 (3.54%); P = 
0.07]. Treatment did not alter the risk of a new IMI 
[4/49 (8.1%) vs. 2/57 (3.5%) for control and treatment, 
respectively; P = 0.30].
The foremilk SCC were lower in the treated glands 
than in control glands [1,595 (95% CI = 1,106–2,300) 
vs. 3,028 (95% CI = 2,091–4,385) geometric mean (× 
1,000) cells/mL for treated and control glands, respec-
tively; P = 0.006]. The difference in log base 2 terms 
was 0.925 between treatment and control. The gland-
level foremilk SCC varied among herds (P = 0.04), 
tended to vary among time periods (P = 0.053), and 
was higher in glands with major compared with a minor 
IMI [4,317 (95% CI = 2,597–7,174) vs. 1,118 (95% CI 
= 856–1,462) geometric mean (× 1,000) cells/mL; P < 
0.001]. There were no interactions among the variables 
left in the model.
Goat Level. Eighty-eight goats were enrolled, 43 in 
the control group and 45 in the treated group. No dif-
ference in age, kidding date, breed distribution, number 
of enrolled goats with 2 glands enrolled, or distribution 
existed among herds in the treatment groups (all P > 
0.1).
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Figure 1. The sensitivity (SE), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV; 95% CI) for any intra-
mammary infection for the California Mastitis Test (CMT) by (a, b) the cut-point and (c, d) DIM using greater than trace as the cut point.
Figure 2. Receiver operator curve for the California Mastitis Test 
(CMT) applied after kidding for predicting the presence of any intra-
mammary infection.
For bacteriological cure, an interaction between treat-
ment group and pathogen type was observed whereby 
in goats with only minor pathogens isolated, treatment 
resulted in a higher cure proportion (P < 0.001). In 
contrast, when a goat had a major pathogen, there was 
no difference in cure proportion between treated and 
control goats (P = 0.16; Table 3).
A total of 41.1% of enrolled does were removed dur-
ing or at the end of lactation. The proportion removed 
did not differ between groups [0.36 (SE = 0.08) vs. 
0.47 (SE = 0.08) for control and treatment groups, 
respectively; P = 0.51]. The proportion removed in-
creased with age, with goats >4 yr old more likely to 
be removed than younger goats [0.29 (SE = 0.08), 0.15 
(SE = 0.08), 0.53 (SE = 0.10), and 0.75 (SE = 0.11) for 
<3, 3–4, 5–7, and >7 yr old, respectively; P < 0.001]. 
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Figure 3. Geometric mean (SEM) foremilk gland level SCC by (a) California Mastitis Test score and (b) DIM and infection status. White 
bars = uninfected glands; black bars = infected glands. Columns with different letters differ at P < 0.05.
Table 1. The bacteriological results from glands with a California 
Mastitis Test (CMT) score of >1 
Item Samples, n %
No growth 233 46.0
CNS 174 34.4
Corynebacterium spp. 65 12.8
Escherichia coli 2 0.4
Streptococcus uberis 3 0.6
Staphylococcus aureus 23 4.5
Serratia spp. 1 0.2
Yeast 3 0.6
Bacillus spp. 1 0.2
Contaminated1 1 0.2
Total 506  
 1More than 3 distinct colony types identified.
Only 6 goats (4 in the control group and 2 in the treat-
ment group) were removed for mastitis-related reasons. 
Two of these goats (1 in each treatment group) died of 
mastitis. Length of lactation between groups did not 
differ [246 (SE = 13) vs. 236 (SE = 16) d for treatment 
and control, respectively; P = 0.87; Figure 4].
Treatment did not affect the composite milk produc-
tion recording SCC [1,596 (95% CI = 1,219–2,090) 
vs. 1,488 (95% CI = 1,132–1,955) geometric mean 
(× 1,000) cells/mL for treated and control goats, re-
spectively; P = 0.67]. No milk production recording 
number by treatment interaction was detected (P > 
0.2; Figure 5a). The SCC varied among herds (P = 
0.02), was higher in goats with a major compared with 
a minor IMI (P = 0.003), increased across lactation (P 
< 0.001), and was higher in >7-yr-old goats compared 
with younger goats (P < 0.001). No interactions were 
observed among the variables left in the model (all P 
Journal of Dairy Science Vol. 93 No. 10, 2010
MCDOUGALL ET AL.4716
Table 2. Descriptive data for the categorical variables of the 2 treatment groups1 
Item 
Control (n = 49) Treatment (n = 57) Total (n = 106)
P-valuen % n % n %
Bacteriology
 CNS 25 51.0 29 50.9 54 50.9 0.84
 Corynebacterium spp. 13 26.5 16 28.1 29 27.4  
 Escherichia coli 0 0.0 1 1.8 1 0.9  
 Staphylococcus aureus 9 18.4 10 17.5 19 17.9  
 Streptococcus uberis 2 4.1 1 1.8 3 2.8  
DIM
 1 17 34.7 32 56.1 49 46.2 0.07
 2 15 30.6 9 15.8 24 22.6  
 3 13 26.5 9 15.8 22 20.8  
 4+ 4 8.2 7 12.3 11 10.4  
Herd
 1 17 34.7 27 47.4 44 41.5 0.31
 2 10 20.4 5 8.8 15 14.2  
 3 13 26.5 14 24.6 27 25.5  
 4 9 18.4 11 19.3 20 18.9  
Breed
 Saanen 24 49.0 38 66.7 62 58.5 0.07
 Cross or other 25 51.0 19 33.3 44 41.5  
California Mastitis Test score
 2 42 85.7 53 93.0 95 89.6 0.22
 3 7 14.3 4 7.0 11 10.4  
Glands enrolled, n
 1 32 65.3 29 50.9 61 57.5 0.13
 2 17 34.7 28 49.1 45 42.5  
Age, yr
 1 9 18.4 14 24.6 23 21.7 0.72
 2–3 14 28.6 14 24.6 28 26.4  
 4–5 11 22.4 8 14.0 19 17.9  
 6–7 7 14.3 11 19.3 18 17.0  
 >7 8 16.3 10 17.5 18 17.0  
1Control = untreated; treatment = 3 infusions at 12-h intervals of 75 mg of sodium ampicillin and 250 mg of sodium cloxacillin.
Table 3. Number and percentage of glands and goats that underwent bacteriological cure by pathogen type and treatment group 
Pathogen1 Group2
Gland level Goat level
Cure, n
Total, n %
Cure, n
Total, n %No Yes No Yes
Minor Control 35 4 39 10.3 29 4 33 12.1
 Treatment 15 30 45 66.7 15 21 36 58.3
 Total 50 34 84 40.5 44 25 69 36.2
Major Control 9 2 10 18.2 8 2 10 20
 Treatment 12 0 12 0.0 9 0 9 0.0
 Total 21 2 23 8.7 17 2 19 10.5
1Minor = CNS or Corynebacterium spp.; major = Staphylococcus aureus, Streptococcus uberis, or Escherichia coli.
2Control = untreated; treatment = 3 infusions at 12-h intervals of 75 mg of sodium ampicillin and 250 mg of sodium cloxacillin.
> 0.10). Goats that cured had lower SCC than those 
that did not [958 (95% CI = 664–1,382) vs. 1,615 (95% 
CI = 1,279–2,038) geometric mean (× 1,000) cells/mL 
for goats that did and did not cure, respectively; P = 
0.005; Figure 5c].
Treatment did not affect the milk solids produc-
tion [0.16 (95% CI = 0.14–0.17) vs. 0.16 (95% CI = 
0.14–0.18) kg/goat per day for treated and control 
goats, respectively; P = 0.97]. No treatment by herd 
test interaction was observed (P = 0.13; Figure 5b). 
The production varied among herds (P < 0.001), was 
lower in goats <3 yr old compared with those that were 
3 or 4 to 6 yr old (P < 0.001), declined with stage of 
lactation (P < 0.001), and was lower in goats treated 
in 2 glands than in those treated in 1 gland (P = 0.03). 
First-order interactions between treatment group and 
age and with herd were not significant (P > 0.3). Milk 
solids production did not differ between goats that did 
or did not cure [0.16 (95% CI = 0.14–0.18) vs. 0.16 
(95% CI = 0.15–0.17) kg/goat per day for goats that 
cured and those that did not, respectively; P = 0.94; 
Figure 5d]. The cost benefit was −NZ$20.39/treated 
doe (Table 4).
DISCUSSION
Knowledge of the CMT result increased the probabil-
ity that a gland would have an IMI compared with not 
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Figure 4. Percentage of enrolled does still in milk by DIM for does 
treated with a combination of ampicillin and cloxacillin (treatment) or 
left as untreated controls (control).
Figure 5. Geometric mean milk production recording (a) SCC (95% CI) and (b) milk solids production (fat and protein; kg/doe per day; 95% 
CI) by milk production recording number for goats with subclinical mastitis that were treated with a combination of ampicillin and cloxacillin 
(black bars) or left as untreated controls (white bars), and (c) SCC (95% CI) and (d) milk solids production (fat and protein; kg/doe per day; 
95% CI) by milk production recording number for goats that did not (black bars) or did (white bars) cure.
having undertaken the CMT. Treatment of subclinical 
IMI resulted in a higher cure proportion and a lower 
foremilk gland-level SCC but no difference in goat-level 
composite SCC, length of lactation, or risk of removal.
The CMT was shown to be useful in screening goats 
early after kidding for the presence of increased SCC 
and for the presence of an IMI. This result extends 
previous studies that had demonstrated that the CMT 
was a useful test later in lactation (Maisi, 1987; Contre-
ras et al., 1996; McDougall et al., 2001). The positive 
predictive values (i.e., the proportion of glands that 
were CMT positive that had an IMI) were 0.30, 0.42, 
and 0.55 when the cut points were >0, greater than 
trace, and >1, respectively. Hence, 70, 58, and 45% 
of glands with a CMT score >0, greater than trace, 
and >1, respectively, did not have an IMI compared 
with 80% for a random sample drawn from the popula-
tion (in which 80% were not infected and 20% were 
infected). However, increasing the cut point reduced 
the sensitivity, which resulted in more truly infected 
glands not being CMT test positive. Were CMT to be 
used as a screening test, increasing the cut point would 
result in fewer test-positive glands and an increased 
proportion of those tested having an IMI. However, 
at population level, more goats with an IMI would be 
CMT test negative and hence be misclassified and as-
sumed uninfected. The objective for use of the CMT in 
the treatment study was to reduce the costs associated 
with bacteriology. Given that bacteriology costs many 
times more than undertaking a CMT, using the CMT 
as a screening test may be cost effective. For example, 
in the treatment study only 36% of glands were CMT 
positive, with a resultant 64% reduction in bacteriology 
costs if all animals were sampled. However, the cost 
of misclassification errors is unknown. In the current 
study only those glands that were CMT and IMI posi-
tive were then enrolled in the treatment study. Thus, 
glands that were CMT test negative but did in fact 
have an IMI were not included in the study and, hence, 
the benefits of treatment were not quantified for this 
group. The negative predictive value of the CMT was 
>90% up to cut point of >1, indicating that <10% 
of infected glands would be misclassified as uninfected 
using the CMT. Because the CMT was positively corre-
lated with SCC, the CMT could be used as a screening 
test of SCC and those does with an increased CMT 
could be withheld from supply to reduce the risk of 
increasing the bulk milk SCC. As previously reported 
in cattle (Sargeant et al., 2001), SCC declines rapidly 
after parturition but infected glands still have higher 
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Table 4. Cost benefit of treatment of does with subclinical mastitis 
Item Value
Extra revenue  
 Milk payment, NZ$/kg of fat and protein 12.00
 Log base 2 difference in SCC 0.925
 Yield decline/unit log base 2 SCC, kg of milk/goat per day 0.016
 Milk solids (fat, protein, and lactose), % 0.101
 Total milk solids benefit, kg/d 0.002
 Days over which SCC was lower 21
 Total milk solids difference, kg/gland 0.03
 Average no. of glands/doe 1.4
 Total value of additional milk attributed to reduced SCC, NZ$/doe 0.29
 Additional DIM over lactation 10
 Average milk solids, kg/d 0.25
 Additional revenue from additional DIM, NZ$/doe 30.47
 Total additional revenue, NZ$/treated doe 30.76
Reduced costs  
 Reduced clinical mastitis incidence 0
 Reduced incidence of new IMI 0
 Reduced culling 0
 Total reduced costs, NZ$/doe 0
Reduced revenue  
 Milk discard, d 4.5
 Total reduced revenue, NZ$/treated doe 13.71
Increased costs  
 California Mastitis Test cost, NZ$/doe 0.39
 Microbiology, NZ$/sample 8
 Proportion CMT positive 0.42
 Treatments, n 3
 Cost/treatment, NZ$ 5
 Labor cost/treatment, NZ$ 1
 Total increased costs, NZ$/doe 37.43
Net position, NZ$/doe −20.39
SCC than uninfected glands, even in early lactation. 
However, in the current study CMT test characteristics 
were not affected by DIM, indicating the utility of this 
test at any stage of lactation.
Treatment increased the cure proportion over no 
treatment, but only in glands and goats in which a mi-
nor, but not major, IMI was present. The bacteriologi-
cal cure rate for the minor pathogens was 67% at gland 
level in the current study. The bacteriological cure rates 
for CNS and other minor pathogens are reported to 
be between 20 and 90% in dairy cattle (Timms and 
Schultz, 1984; Deluyker et al., 2005; Pyörälä and Ta-
ponen, 2009). The cure rate of the major pathogens, 
predominantly S. aureus, was not improved by treat-
ment in the current study. Bacteriological cure of S. 
aureus is reported to range between 4 and 92% in dairy 
cows, but is commonly <30% (Barkema et al., 2006). 
An Italian study found no evidence of penicillin resis-
tance in S. caprae or S. epidermidis of caprine origin 
(Moroni et al., 2005). The antimicrobial sensitivity 
of the isolates in the current study was not assessed. 
However, zone diffusion testing of 104 CNS and 7 S. 
aureus isolates from the same herds in the season pre-
ceding the study found that 29 and 3% of the CNS 
were penicillin G and oxacillin resistant, respectively, 
whereas none of the S. aureus isolates were resistant to 
either penicillin or oxacillin (S. McDougall; unpublished 
data). This suggests that the low cure rate of S. aureus 
may be unrelated to antimicrobial sensitivity. In the 
current study, the overall cure proportion was biased 
downward because all major gram-positive pathogens 
were by design enrolled compared with only 50% of the 
minor pathogens. Hence, if all glands with an IMI had 
been treated, a higher overall cure proportion would 
likely have resulted because of the greater cure rates of 
the minor pathogens.
Because of the heterogeneity of the CNS, specia-
tion is required to advance the understanding of the 
effect, sources, transmission mechanisms, and control 
options for this group of bacteria (Zadoks and Watts, 
2009). Identification to species level using phenotypic 
characteristics may result in lower typeability and ac-
curacy than using genotypic techniques (Sampimon et 
al., 2009; Zadoks and Watts, 2009) with the resultant 
risk of misclassification errors. The current study is ap-
parently the first to use a genotypic technique for CNS 
isolates of caprine origin. Because it is both accurate 
and relatively cheap, tDNA-PCR was used. The library 
used for this technique was updated recently for the 
identification of bovine CNS isolates from milk and teat 
apices (Supré et al., 2009). Because strain differences 
might occur between caprine and bovine CNS isolates, 
tDNA-PCR was supplemented with sequencing of the 
rpoB housekeeping gene in every case in which there 
was any doubt. Indeed, strain differences between these 
hosts were seen in this study. There were some caprine 
CNS isolates of which the tDNA pattern seemed similar 
to that of S. simulans, but these formed a separate 
cluster. After sequencing, it was confirmed that these 
isolates belonged to S. simulans (>98% sequence 
similarity with GenBank entries). Eight different CNS 
species were isolated in the current study. All of these 
had been reported previously as having been isolated 
from goat milk using phenotypic techniques (Contreras 
et al., 2007). The distribution of CNS species varied 
among herds, with only S. simulans, the most prevalent 
pathogen, isolated from each herd in the current study. 
In contrast, S. simulans has generally been reported 
to be one of the less common CNS in previous studies 
(Contreras et al., 2007). However, previous studies have 
used phenotypic tests, such as the API Staph ID 32, 
which have been shown to correctly identify only 22% 
of S. simulans (Sampimon et al., 2009). The number 
of isolates of each species was too small to analyze the 
effect of CNS species on SCC or on bacteriological cure 
rate following treatment. The CNS species appear to 
vary in pathogenicity and persistence, and it has been 
hypothesized that differences in milking management 
techniques, teat antisepsis, and milk machine function-
ality may contribute to observed differences in preva-
lence of CNS species among herds (Contreras et al., 
2007). Further studies are required to understand the 
epidemiology of the various CNS species in goats and, 
hence, to provide control methods for them.
Knowledge of CNS species did not alter the infer-
ences drawn from the current study. It is feasible that 
one CNS species was present before treatment and 
cured but that the gland became reinfected with a dif-
ferent CNS species. In this case, if the CNS were not 
speciated, the treatment would have been defined as 
not effective. Six new infections with CNS were found 
in the current study, an incidence rate of 6 per 2,331 
gland-days, indicating that transmission of CNS was 
occurring in these herds. However, from the 33 glands 
from which CNS species were isolated before and after 
treatment, we found only 1 example of a different CNS 
species being isolated after treatment. Other studies 
using phenotypic techniques have shown that CNS are 
persistent in goats, with the duration of infection aver-
aging 1.3 mo for S. caprae, 3.4 mo for S. epidermidis, 
and 1.9 mo for other CNS spp. where no treatments 
were given (Moroni et al., 2005). Similarly several CNS 
species persisted for up to 7 mo (Contreras et al., 1997). 
However, these studies were performed using phenotypic 
methods, which lack accuracy; therefore, interpretation 
and comparison should be done with care. As is the 
limitation of almost all studies (using phenotypic as 
well as molecular methods), for species-level identifica-
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tion, only 1 colony forming unit of every organism with 
the same growth characteristics on the esculin-blood 
agar plate was selected. If more than 1 CNS species 
with the same growth characteristics was present on 
the plate, this could have been missed. In addition, to 
draw accurate conclusions on persistency or reinfection 
after treatment, strain typing should be performed on 
all isolated bacteria.
Despite differences in gland-level SCC and cure 
proportion, no differences in milk production or in 
goat-level SCC between treatments were observed. The 
apparent discrepancy in SCC results between the gland-
level and goat-level data may be attributed to the fact 
that 1) the gland-level samples were foremilk samples 
whereas the goat-level samples were composite of both 
glands across 2 whole milkings, 2) the gland-level SCC 
were assessed at 14 and 21 d posttreatment whereas 
the goat composite samples were collected at 4 time 
points across lactation, commencing at an average of 47 
d after kidding (i.e., about 40 d after treatment), and 
3) the individual gland SCC include only the infected, 
enrolled glands whereas the composite sample includes 
glands that were uninfected and unenrolled. Both data 
are presented because the gland-level assessment is the 
more precise way of assessing treatment effect, whereas 
the herd owners have access to only the composite herd 
test SCC data to judge treatment success. No measur-
able effect on milk production was found in cows with 
CNS clinical mastitis, whereas S. aureus infection de-
pressed milk production for 8 wk after diagnosis (Gröhn 
et al., 2004). Additionally, it has been concluded that 
treatment of subclinical mastitis during lactation has 
no effect on subsequent milk production in dairy cows 
(McDermott et al., 1983; St Rose et al., 2003). However, 
milk yield is estimated to be reduced by between 16 
and 20 g/gland per day with each increase in log base 
2 SCC in goats (de los Campos et al., 2006). In that 
same study there was evidence of nonindependence of 
glands; that is, infection in one gland increased SCC in 
the other and potentially reduced production. However, 
increased milk yield by an uninfected gland in com-
pensation for reduced production by an infected gland 
remains a possibility. It is also feasible that an IMI may 
have had irreversible effects on the mammary gland 
before treatment was instigated.
The partial budget suggested that it was not cost 
effective to undertake treatment of does with subclini-
cal IMI in early lactation despite the increase in cure 
rate and the reduction in the gland-level foremilk SCC. 
However, not all potential benefits were measured in 
the current study. For example, in dairy cows, the 
probability that an infected cow infects another cow 
was an important factor in the cost benefit of treating 
subclinical mastitis. By successfully curing an existing 
IMI, the risk of secondary infection and its associated 
costs is reduced (Swinkels et al., 2005). It was beyond 
the scope of the current study to assess the effect of 
reduced prevalence of infection on the incidence of new 
infections across the herds, and no data appear to exist 
quantifying the transmission of IMI within goat herds 
with or without treatment of existing IMI. Thus, any 
benefits associated with a reduced incidence of new 
infections across the whole herd as a result of lower 
prevalence of IMI could not be included in the current 
analysis.
It is concluded that use of the CMT within 10 d of 
kidding provided moderate sensitivity and specificity 
for detecting IMI. The CMT score was positively as-
sociated with the gland-level foremilk SCC, so it could 
be used as a screening test during the first few days of 
lactation to identify goats with high SCC that should 
not enter the supply. Treatment of subclinical mastitis 
resulted in an increased cure proportion compared with 
no treatment. However, this was only true for minor 
pathogens. Where a gland (or goat) was infected with 
a major pathogen, treatment had no benefit compared 
with no treatment. Treatment also reduced foremilk 
gland-level SCC but had no effect on subsequent com-
posite goat-level SCC, production, or survival. Eco-
nomic analysis suggests that treatment of subclinical 
mastitis may not be cost effective in dairy goats.
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